Prostate Cancer Canada - Prostate Cancer Canada

In The News

PSA Fitness (Power, Strength & Agility)
HALIFAX, N.S., January 16, 2012/CNW/ Prostate Cancer Canada Atlantic is proud to announce the launch of PSA Fitness (Power, Strength & Agility), a free nine week exercise program for men who have been diagnosed with prostate cancer. PSA Fitness, resistance training and yoga, is an important patient-centered therapy for prostate cancer survivors in Halifax.

TELUS donation to support Prostate Cancer Canada
Toronto, ON- January 13, 2012- On January 10th, Prostate Cancer Canada received a generous donation of $100,000 from TELUS at the launch of the TIEd Together exhibition. TELUS’ donation was made possible through the Canadian Football League Grey Cup cause marketing campaign. The donation will support Prostate Cancer Canada’s ongoing efforts to eliminate the disease through research, education, support and awareness.

Click For Information Archive

Prostate Cancer News

In the past few years more and more discoveries regarding prostate cancer testing, diagnosis, treatment options have been discovered. Please read through this section of our website to learn more about the latest discoveries relating to prostate cancer.

Displaying results 1-5 (of 47)

|< < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 > >|

Important news about Vitamin E and prostate cancer | 12/6/2011

It was recently published in the Journal of the American Medical Association (JAMA) that the “SELECT Trial” for prostate cancer prevention with oral Vitamin E and selenium supplementation, alone or In combination, compared to placebo, was negative i.e. there was no benefit with the supplements in terms of prostate cancer prevention.

PCC position on PSA testing | 11/2/2011

The United States Preventive Services Task Force (USPSTF) has recently recommended against the use of prostate specific antigen (PSA) to screen for prostate cancer in asymptomatic men. In light of this development, Prostate Cancer Canada (PCC) wishes to clarify its position on PSA testing. PCC continues to support and recommend PSA testing for the early detection of prostate cancer. PCC emphasizes that, applied appropriately, PSA is a useful test. A full discussion with the patient on the pros and cons of PSA testing should continue to be an integral part of patient management.

A made-in-Canada view of PSA testing | 10/25/2011

A“tizzy” is perhaps the best way to describe the effects of the recommendation released earlier this month by the United States Preventive Services Task Force, a panel of medical professionals that provides guidance on preventive health measures. The recommendation concerned the prostate-specific antigen (PSA) test, which is conducted on men to screen for cancer of the prostate gland, the most common form of cancer experienced by Canadian men.

While no one disputes the PSA test helps to detect cancer, the task force decided on the basis of five large clinical trials that the risks of prostate cancer treatment outweighed the risks of prostate cancer itself. In other words, the task force was telling healthy men they were better off not knowing whether they had prostate cancer.

Early Detection Guidelines Update | 10/6/2011

Prostate Cancer Canada (PCC) strongly believes in the merits of screening for prostate cancer and actively encourages all men over the age of 40 to have the prostate cancer discussion with their doctor and begin PSA (Prostate Specific Antigen) testing.

Edmonton Prostate Health Clinic receives $1m Movember funded PCC donation | 10/4/2011

A $1 million Movember funded donation from Prostate Cancer Canada has helped build the $10 million Edmonton prostate clinic in Edmonton.

Displaying results 1-5 (of 47)

|< < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 > >|

Thanks for the follows! @RabyInstitute @THENUMBERUNEO @BBSupport @JackieManthorne @TELUS @ABJuniorCurling @PatientStories1 @healthfinder
Follow Us On Twitter

Prostate Cancer Canada
2 Lombard Street, 3rd Floor, Toronto
Ontario M5C 1M1, Canada
info@prostatecancer.ca

Telephone: 416-441-2131
Toll-free: 1-888-255-0333
Fax: 416-441-2325